Probity Advisors Inc. lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 22.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,303 shares of the company’s stock after selling 1,496 shares during the period. Probity Advisors Inc.’s holdings in Zoetis were worth $338,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds also recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. boosted its holdings in Zoetis by 16.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock worth $100,000 after buying an additional 230 shares in the last quarter. Point72 Asia Hong Kong Ltd purchased a new stake in Zoetis during the first quarter worth about $111,000. Harfst & Associates Inc. boosted its holdings in Zoetis by 16.1% during the second quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock worth $117,000 after buying an additional 260 shares in the last quarter. Almanack Investment Partners LLC. purchased a new stake in Zoetis during the second quarter worth about $119,000. Finally, Peddock Capital Advisors LLC purchased a new stake in Zoetis during the second quarter worth about $140,000. 93.04% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This article was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.com-unik.info/2017/10/31/zoetis-inc-zts-shares-sold-by-probity-advisors-inc.html.
Shares of Zoetis Inc. (NYSE ZTS) traded up 0.90% during trading on Tuesday, hitting $63.81. 1,182,651 shares of the company traded hands. The stock has a market cap of $31.21 billion, a price-to-earnings ratio of 36.07 and a beta of 1.02. Zoetis Inc. has a one year low of $46.86 and a one year high of $66.35. The firm has a 50 day moving average price of $64.49 and a 200-day moving average price of $61.93.
Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, hitting the consensus estimate of $0.53. The business had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The firm’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period last year, the company posted $0.49 earnings per share. Analysts predict that Zoetis Inc. will post $2.34 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Thursday, November 9th will be issued a dividend of $0.105 per share. This represents a $0.42 annualized dividend and a dividend yield of 0.66%. The ex-dividend date is Wednesday, November 8th. Zoetis’s dividend payout ratio is currently 23.73%.
ZTS has been the topic of a number of research analyst reports. BMO Capital Markets set a $65.00 price objective on shares of Zoetis and gave the stock a “hold” rating in a report on Wednesday, October 25th. BidaskClub raised shares of Zoetis from a “buy” rating to a “strong-buy” rating in a report on Tuesday, September 12th. Deutsche Bank AG reaffirmed a “buy” rating and issued a $65.00 price target (up previously from $62.00) on shares of Zoetis in a report on Monday, July 17th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $75.00 price target on shares of Zoetis in a report on Tuesday, October 24th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $65.00 price target on shares of Zoetis in a report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $65.76.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
What are top analysts saying about Zoetis Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zoetis Inc. and related companies.